Novel therapeutics target Parkinson’s & Alzheimer’s
Novel neuroprotective and restorative peptides that possess unique mitochondrial bioactivity offer the promise of restoring function and preventing further damage caused by neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease. The peptides can be delivered via non-invasive means across the BBB to distribute throughout the brain. Initially focusing on Parkinson’s, the lead candidates have demonstrated strong neuroprotective and restorative properties in rodent and non-human primate models following intranasal dosing, without evidence of adverse effects. Next steps are to continue pre-clinical studies to ultimately lead to regulatory FDA approval for clinical trials.
The molecular platform’s central mechanisms of action suggest a collection rich in candidates for the noninvasive treatment of a wide number of brain diseases.
Avast Therapeutics has formally acquired the exclusive option rights from the University of Kentucky to commercially develop, license, and negotiate the intellectual property developed in the labs of the Founders, which includes two awarded US Patents and additional pending International Patent applications.